Key Highlights
Earlier menopause is associated with significantly accelerated trajectories of chronic disease development and multimorbidity progression. Women experiencing premature menopause (before age 40) demonstrated a 32% increased risk of developing first chronic disease compared to those with menopause after age 50. The association followed a graded pattern, with progressively earlier menopause corresponding to incrementally higher risks across all transition states analyzed. These findings underscore the potential value of earlier menopause as a clinical marker for intensified preventive health monitoring in women.
Background: The Clinical Significance of Menopausal Timing
Menopause represents a fundamental transition in women’s reproductive lives, typically occurring between ages 45 and 55 years. The timing of this transition has increasingly been recognized as a biomarker for overall health trajectories, with accumulating evidence suggesting that earlier menopause is associated with elevated risks of cardiovascular disease, osteoporosis, cognitive decline, and all-cause mortality. However, the specific mechanisms through which menopausal timing influences the development of multimorbidity—the coexistence of two or more chronic conditions—remain incompletely understood.
Multimorbidity represents one of the most pressing challenges in contemporary healthcare systems, particularly among aging populations. The simultaneous presence of multiple chronic conditions complicates clinical management, reduces quality of life, and substantially increases healthcare utilization and costs. Understanding the factors that accelerate or delay the onset of multimorbidity is therefore critical for developing effective prevention strategies and allocating healthcare resources appropriately.
The study by Li and colleagues addresses this knowledge gap by investigating whether age at menopause is associated with the trajectory of multimorbidity progression using sophisticated multi-state modeling techniques that capture the dynamic nature of disease development over time. This approach represents a methodological advancement over traditional Cox proportional hazards models that typically analyze single outcomes in isolation.
Study Design and Population
This retrospective cohort study utilized data from the UK Biobank, a large-scale prospective study comprising approximately 500,000 participants aged 40-69 years at baseline enrollment between 2006 and 2010. The analysis focused specifically on 121,017 postmenopausal women with complete baseline and menopausal data who were followed for a median period of 8.6 years.
The study employed a multi-state modeling framework, which conceptualizes health trajectories as transitions between discrete states: from an initial healthy state to first chronic disease (FCD), from FCD to multimorbidity, and from each of these states to mortality. This analytical approach allows for the examination of how exposure variables—in this case, menopausal age—influence not only the risk of developing chronic conditions but also the subsequent progression to more complex health states.
Menopausal age was categorized into four groups: premature menopause (before age 40 years), early menopause (ages 40-44 years), relatively early menopause (ages 45-49 years), and reference group (age 50 years or older). The definition of multimorbidity encompassed 35 chronic conditions identified through self-reported physician diagnoses, hospital admissions, and national registry data.
Cox proportional hazards models served as the primary analytical tool, with hazard ratios (HR) and 95% confidence intervals (CI) calculated to quantify the associations between menopausal age and each transition state after adjustment for potential confounders including socioeconomic status, lifestyle factors, body mass index, and hormone replacement therapy use.
Key Findings: Graded Association Between Menopausal Timing and Disease Trajectories
Over the median follow-up period of 8.6 years, substantial numbers of clinical events occurred: 86,821 women (71.7%) developed a first chronic disease, 42,237 women (34.9%) progressed to multimorbidity, and 10,527 participants (8.7%) died. These baseline event rates provide important context for interpreting the relative risk estimates associated with earlier menopause.
Transition from Health to First Chronic Disease
The multi-state model analysis revealed a clear graded relationship between menopausal age and the risk of transitioning from a healthy state to first chronic disease. Compared with women who experienced menopause after age 50 years (the reference group), the hazard ratios for developing first chronic disease were:
Women with premature menopause (before age 40) demonstrated a 32% increased risk (HR = 1.32, 95% CI: 1.28-1.36). This represents the most substantial risk elevation observed in the study, indicating that extremely early menopause may identify a particularly vulnerable subgroup warranting enhanced clinical surveillance.
Women with early menopause (ages 40-44) showed a 14% increased risk (HR = 1.14, 95% CI: 1.11-1.17). The confidence interval excludes the null value, confirming statistical significance and suggesting meaningful clinical relevance despite the more modest effect size.
Women with relatively early menopause (ages 45-49) experienced a 3% increased risk (HR = 1.03, 95% CI: 1.01-1.05). While this represents the smallest effect estimate, the association remained statistically significant and may have public health implications given the large population of women in this menopausal age range.
Transition from First Chronic Disease to Multimorbidity
The analysis of disease progression revealed similar patterns for the transition from first chronic disease to multimorbidity. Women who had already developed one chronic condition demonstrated differential risks of accumulating additional conditions based on their menopausal timing:
Premature menopause was associated with a 22% increased risk of progressing from FCD to multimorbidity (HR = 1.22, 95% CI: 1.17-1.27).
Early menopause corresponded to a 13% increased risk (HR = 1.13, 95% CI: 1.09-1.16).
Relatively early menopause was linked to a 6% increased risk (HR = 1.06, 95% CI: 1.03-1.08).
Importantly, these risk elevations persisted after adjustment for potential confounding variables, suggesting that the association between menopausal timing and multimorbidity trajectories is at least partially independent of lifestyle and socioeconomic factors that might otherwise explain these relationships.
Mortality Considerations
While the study reported mortality as an outcome, the multi-state model results specific to mortality transitions from each health state were not fully detailed in the available abstract. However, the overall burden of mortality events (10,527 deaths, 8.7% of the cohort) combined with the observed patterns of disease development suggests that earlier menopause may also influence survival trajectories, consistent with prior literature demonstrating associations between menopausal timing and all-cause mortality.
Expert Commentary: Mechanistic Insights and Clinical Implications
The findings from this study contribute to a growing body of evidence positioning earlier menopause as a potentially modifiable risk marker rather than merely a reproductive characteristic. Several mechanistic pathways may explain these observed associations.
Biological Plausibility
Estrogen exerts protective effects across multiple organ systems, including the cardiovascular system, bone tissue, and brain. The premature decline of estrogen associated with earlier menopause may accelerate atherosclerotic processes, bone mineral density loss, and neurocognitive changes that collectively increase susceptibility to chronic disease development. Additionally, earlier menopause may serve as a marker for underlying biological aging processes that operate across multiple physiological systems simultaneously—a concept sometimes referred to as “biological age” or “systemic aging.”
Genetic factors may also contribute to both menopausal timing and chronic disease susceptibility. The identification of specific genetic variants associated with both reproductive aging and cardiovascular disease risk suggests shared mechanistic pathways that warrant further investigation.
Clinical Implications
From a clinical perspective, these findings suggest that women with earlier menopause—whether premature, early, or relatively early—may benefit from more intensive preventive health monitoring. While the absolute risk differences may appear modest for individual women, the population-level implications are substantial given the high prevalence of earlier menopause in the general population and the enormous burden of multimorbidity in aging societies.
Healthcare providers might consider earlier menopause as a flag for proactive screening and risk factor modification, including aggressive management of cardiovascular risk factors, bone density monitoring, and lifestyle interventions targeting diet, physical activity, and smoking cessation.
Study Limitations
Several limitations merit consideration when interpreting these findings. The UK Biobank cohort, while large, tends to be more health-conscious and less ethnically diverse than the general population, potentially limiting generalizability. The reliance on self-reported menopausal age introduces potential recall bias, and the observational design precludes definitive causal conclusions. Residual confounding from unmeasured factors cannot be excluded despite careful statistical adjustment.
Additionally, the study’s definition of multimorbidity (≥2 of 35 conditions) may not capture all clinically relevant patterns of disease clustering, and the follow-up period, while substantial, may not fully capture long-term trajectories extending into older age when multimorbidity becomes most prevalent.
Conclusion: Toward Personalized Preventive Strategies
This large-scale multi-state analysis of UK Biobank data provides compelling evidence that earlier menopause is associated with accelerated trajectories of multimorbidity progression, affecting both the initial transition from health to chronic disease and the subsequent progression to multimorbidity. The graded nature of this association—with progressively earlier menopause corresponding to incrementally higher risks—strengthens the credibility of a causal relationship and suggests potential biological mechanisms linking reproductive aging to systemic health trajectories.
These findings have important implications for clinical practice and public health policy. Women experiencing earlier menopause represent a identifiable subgroup who may benefit from intensified preventive interventions, earlier screening for chronic conditions, and comprehensive risk factor management. From a research perspective, future studies should investigate whether interventions targeting modifiable risk factors can mitigate the elevated risks associated with earlier menopause and should explore the genetic and environmental determinants of both reproductive timing and chronic disease susceptibility.
The recognition of menopausal timing as a potential marker of biological aging and disease susceptibility represents an important step toward more personalized approaches to women’s health that integrate reproductive history with contemporary risk assessment strategies. As healthcare systems grapple with the growing burden of multimorbidity, understanding the factors that accelerate or delay disease progression becomes increasingly critical for developing effective prevention and management strategies.
Funding and Conflicts of Interest
This study utilized data from the UK Biobank (application number not specified in the available abstract). The authors declared no conflicts of interest. Full disclosure of funding sources and potential conflicts will be available upon publication of the complete manuscript.
References
Li M, Liu T, Zhou H, Yu X, Wang H, Zheng L, Wang Z, Han X, Ren X, Lu X, Tian W. Age at Menopause and Trajectories of Multimorbidity Progression to Mortality: A Multi-State Analysis of UK Biobank Data. BJOG : an international journal of obstetrics and gynaecology. 2026-04-04. PMID: 41934138.
